Act Now on CRISPR Babies
By Editors,
Nature
| 06. 11. 2019
Another researcher has announced controversial plans to gene edit babies. The scientific community must intervene.
A worldwide debate is under way on how to regulate gene editing in human sperm, eggs or embryos.
A researcher steps forward and says he has plans to edit the genes of babies. He wants to alter a gene called CCR5 to protect children from HIV. He seems to have the skills, tools and position to do so — and he starts to tell other scientists about his plans.
When Chinese scientist He Jiankui did this, the story went famously wrong. Jiankui pushed ahead with his work quietly, and last November announced the birth of the world’s first gene-edited babies. He was quickly and universally condemned for acting recklessly and ignoring risks. Meanwhile, scientists whom He had told about the work beforehand were criticized for not raising the alarm.
Now this scenario is playing out again. Nature this week reports that molecular biologist Denis Rebrikov at the Pirogov Russian National Research Medical University in Moscow says that he plans to create babies with an edit of the same gene. The proposals are controversial, and already scientists are raising doubts...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...